

December 5, 2022

Kidswell Bio Corporation

Code: 4584 (TSE Mothers)

Masaharu Tani, President & CEO

## Announcement of participation in the open innovation initiative “i2.JP (Innovation Infusion Japan)” led by AstraZeneca K.K.

Tokyo, December 5, 2022 – Kidswell Bio Corporation (KWB) is delighted to announce that KWB participated in the open innovation initiative in healthcare field “i2.JP (Innovation Infusion Japan)” led by AstraZeneca K.K. (Headquarters in Kita-ku, Osaka, Takafumi Horii, Representative Director and President) as a partner company.

With the mission of healthcare innovation engine to realize “patient centricity”, i2.JP is an open innovation initiative to connect healthcare professionals, local governments, academia and private companies, designed to jointly work out collective and practical optimal answers toward the solution of issues in the healthcare field.

KWB has been conducting cell therapy (regenerative medicine) business utilizing stem cells from human exfoliated deciduous teeth (SHED) as a growth driver to improve KWB’s corporate value and accelerating research and development to launch cell/gene therapy for pediatric, rare and intractable diseases with SHED master cell bank (MCB) completed in August 2022. As a partner company, KWB will actively collaborate with AstraZeneca, other partner companies and organizations involved in this initiative, and will tackle four challenges (1. realize “patient centricity”, 2. deliver added value solution to healthcare professionals, 3. discover and develop new technologies contributing to patients and healthcare professionals, 4. optimize healthcare systems) through KWB’s cell therapy (regenerative medicine) business.

Related press releases and presentations:

- [Presentation] Medium Term Strategic Plan -KWB2.0-  
[https://www.kidswellbio.com/Portals/0/resources/pdf/en/Presentation\\_KWB%202.0%20Full%20version\\_ENG.pdf?TabModule583=0](https://www.kidswellbio.com/Portals/0/resources/pdf/en/Presentation_KWB%202.0%20Full%20version_ENG.pdf?TabModule583=0)
- Announcement of completion of SHED Master Cell Bank in compliance with GMP  
[https://www.kidswellbio.com/Portals/0/20220831\\_SHED%20MCB%20Press%20Release.pdf?TabModule583=0](https://www.kidswellbio.com/Portals/0/20220831_SHED%20MCB%20Press%20Release.pdf?TabModule583=0)

- [Presentation] SHED Master Cell Bank completed  
[https://www.kidswellbio.com/Portals/0/resources/pdf/en/20220831\\_SHED%20MCB%20Presentation.pdf?TabModule583=0](https://www.kidswellbio.com/Portals/0/resources/pdf/en/20220831_SHED%20MCB%20Presentation.pdf?TabModule583=0)
- Announcement of a patent application on cell therapy for cerebral palsy utilizing SHED with Tokai National Higher Education and Research System  
[https://www.kidswellbio.com/Portals/0/resources/pdf/en/20221024\\_01.pdf?TabModule583=0](https://www.kidswellbio.com/Portals/0/resources/pdf/en/20221024_01.pdf?TabModule583=0)
- Announcement of publication of the research articles in collaboration with Hamamatsu University School of Medicine  
[https://www.kidswellbio.com/Portals/0/resources/pdf/en/20221107\\_01.pdf?TabModule583=0](https://www.kidswellbio.com/Portals/0/resources/pdf/en/20221107_01.pdf?TabModule583=0)
- Announcement of publication of the third research article in collaboration with Hamamatsu University School of Medicine  
[https://www.kidswellbio.com/Portals/0/resources/pdf/en/20221128\\_02.pdf?TabModule583=0](https://www.kidswellbio.com/Portals/0/resources/pdf/en/20221128_02.pdf?TabModule583=0)

#### About Kidswell Bio Corporation (KWB)

Kidswell Bio Corporation will challenge pediatric disease as a new field, in addition to intractable and rare diseases on which KWB has also been focusing for R&D. We would like to contribute to children who have hopes and dreams for their bright future. Furthermore, with our biotech expertise and children's potential vital force such as SHED, we envision creating new pharmaceuticals and therapeutics for all people under "Kids Well, All Well."

Contact:

Kidswell Bio Corporation

Tel: +81-3-6222-9547 Mail: [info@kidswellbio.com](mailto:info@kidswellbio.com)